No causative genes, inheritance patterns, or molecular mechanisms are documented in the current certified dataset for pemphigus as an umbrella classification. The six recognized subtypes within the pemphigus spectrum may have distinct underlying genetic and immunological mechanisms captured within their individual disease records.

No specific diagnostic methods or criteria are documented in the current certified dataset for pemphigus as a parent-level classification. Diagnostic approaches specific to individual subtypes such as pemphigus vulgaris, pemphigus foliaceus, and related entities are not captured at this classification level.

No FDA-approved treatments, foundational therapies, orphan drug designations, or patient assistance programs are documented in the current certified dataset for pemphigus as a parent-level classification. Treatment data specific to individual subtypes within the pemphigus spectrum would be found within their respective disease records.

No natural history data, outcome information, or prognostic metrics are present in the current certified data for pemphigus as an umbrella classification. Prognosis varies by subtype and is not captured at this parent-classification level.

Several active clinical trials are registered for pemphigus and pemphigus-associated conditions, with 17 active trial records documented on ClinicalTrials.gov. Documented investigations include studies of CAR-T cell therapies targeting pemphigus vulgaris, a rituximab-based combination regimen compared against rituximab monotherapy as first-line treatment, studies of personalized maintenance therapy protocols, a broad autoimmune blistering disease registry study, and assessments of oral manifestations and periodontal status in pemphigus vulgaris. Multiple studies are actively recruiting participants.